My Treatment Approach: Optimizing Care for Relapsed / Refractory Multiple Myeloma: Translating Evidence to Clinical Practice - Episode 4

Expert Perspectives: Navigating the Evolving Treatment Landscape in Early Relapse MM

August 21, 2024

Robert Z. Orlowski, MD, PhD, Jonathan L. Kaufman, MD

The panelists explore the evolution of treatment approaches for patients with relapsed/refractory multiple myeloma who have undergone 1-3 lines of therapy, with a particular focus on the implications of increased anti-CD38 monoclonal antibody usage in newly diagnosed or early relapse cases.

EP. 1: Clinical Scenario I: 68-yr Old Man with Early Relapse MM

EP. 2: Clinical Insights on Next Treatment Approach Steps

EP. 3: Real Life Clinical Practice Use of Selinexor: Dosing Strategies, Supportive Care, and Strategies to Incorporate into Novel Selinexor-Based Regimens

Now Viewing

EP. 4: Expert Perspectives: Navigating the Evolving Treatment Landscape in Early Relapse MM

EP. 5: Overview of CAR T-cell Therapy Options in R/R MM

EP. 6: Expert Perspectives: Selinexor Role in the Changing Treatment Landscape in MM and Key Takeaways

EP. 7: Patient Profile: 53-Year-Old Man with Heavily Pre-Treated MM including T-cell Directed Therapy

EP. 8: Clinical Insights on the Patient Presentation & Treatment Course

EP. 9: Challenges of Treatment Sequencing in Heavily Pre-Treated R/R MM: Expert Insights

EP. 10: Potential Novel Lab Monitoring & Key Takeaways for Heavily Pre-Treated R/R MM

EP. 11: Clinical Pearls & Unmet Needs in Early and Late Relapse R/R MM

Video content above is prompted by the following:

How has the treatment landscape evolved for patients with r/r MM, post 1-3 lines of therapy, especially in the setting of increasing use of anti-CD38 monoclonal antibodies in the newly diagnosed or early relapse space?
- What are currently available treatment options?
What is the utility of Selinexor in the post anti-CD38-monoclonal antibody setting?